

Serial No. 10/578,013 - - - - 4

REMARKS

Claims 27 and 29 are pending in this application.

Claims 1-26, 28, and 30-33 are canceled without prejudice.

Claim 27 has been allowed.

Amendments to the Specification.

An obvious typographical error is corrected in paragraph [0004] on page 1 of the specification. No new matter is added by this amendment.

Interview Summary.

Applicant's counsel, Robert Ross, conducted a phone interview with Examiner Kinsey White on August 5, 2008. Claim 29 was discussed. Claim 29 had been rejected as allegedly failing to comply with the written description requirement. Applicant pointed out that the stated reasons for the written description rejection (i.e., the use of the term "functional fragment"), did not apply to this claim. It was agreed that written description rejection was not applicable to claim 29, and that claim 29 was allowable over the prior art of record, since the claimed fragments or portions of SEQ ID NO: 4 have not been disclosed. Claim 29 is now amended to clarify that the claim is directed to portions of SEQ ID NO: 4 by inserting the word "consecutive" between "8-40" and "amino acid residues of SEQ ID NO: 4." No new matter is added, as the description refers to fragments, which clearly refer to portions consisting of consecutive amino acid residues.

Conclusion.

Reconsideration and allowance of all claims is solicited.

Respectfully submitted,

By _____

Arne M. Olson (Reg. No. 30,203)

Dated: September 2, 2008

OLSON & CEPURITIS, LTD.
20 North Wacker Drive, 36th Floor
Chicago, Illinois 60606
(312) 580-1180